Transgene gains from Roche deal

19 August 2007

French biopharmaceutical firm Transgene has posted a strong increase in total revenues and a move into profitability for the first six months of 2007, helped by progress for its strategic partnership with Swiss drug major Roche on TG 4001/R3484, in development for the treatment of precancerous cervical lesions caused by human papilloma virus infection.

Turnover for the reporting period reached 24.7 million euros ($33.7 million) compared with 2.8 million in the like, year-earlier six months, resulting in a net profit of 8.5 million euros versus a loss of 10.6 million euros. Contributing to this result were payments from Roche, including 13.0 million euros upfront and a 10.0 million-euro near-term milestone received in June.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight